Post-earnings recap
Reported
Wed, May 1, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
United Therapeutics reported a strong EPS figure, exceeding expectations by a significant margin. However, the stock fell by 3.19% in reaction, likely due to the lack of revenue data and forward guidance. Investors may be cautious as the company did not provide clarity on future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.58 | N/A | +24.52% |
| Revenue | N/A | N/A | N/A |
Management expressed confidence in the company's future prospects, particularly regarding their pipeline. However, they did not provide specific guidance for upcoming quarters.
Management highlighted the strong performance in EPS despite not providing revenue figures.
They emphasized ongoing investments in research and development.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—